Therefore, this study aimed to elucidate how arctigenin inhibited CRC through the PI3K-AKT-mTOR signaling pathway using in vivo experiments (establishing tumor xenograft and liver-lung metastasis models) and in vitro experiments (cell biology experiments). This evidence concerns the gene MTOR and colorectal carcinoma.